SCHEMBL30248409

SCHEMBL30248409

O=C(Nc1ccc2cc[nH]c2c1)NC(CO)c1ccc2c(c1)N(Cc1ccccc1)CCS2

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 15/20 0.48
KDM4E B2RXH2 7/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
GFER P55789 4/20 0.42
GLA P06280 2/20 0.42
SMN1; SMN2 Q16637 6/20 0.42
TP53 P04637 4/20 0.42
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25028042 1.00 MAPT (0.48) MAPTKDM4EALDH1A1HPGDGFER
SCHEMBL29227011 1.00 MAPT (0.48) MAPTKDM4EALDH1A1HPGDGFER
SCHEMBL29227188 1.00 MAPT (0.48) MAPTKDM4EALDH1A1HPGDGFER
SCHEMBL30248582 0.94 MAPT (0.47) MAPTKDM4EALDH1A1HPGDGFER
SCHEMBL25028040 0.94 MAPT (0.47) MAPTKDM4EALDH1A1HPGDGFER
SCHEMBL29227209 0.94 MAPT (0.48) MAPTKDM4EALDH1A1HPGDGFER
SCHEMBL25028045 0.92 MAPT (0.46) MAPTKDM4EALDH1A1HPGDGFER
SCHEMBL30248575 0.92 MAPT (0.46) MAPTKDM4EALDH1A1HPGDGFER
SCHEMBL25028043 0.91 MAPT (0.46) MAPTKDM4EALDH1A1HPGDGFER
SCHEMBL30248562 0.91 MAPT (0.46) MAPTKDM4EALDH1A1HPGDGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384268-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS Curadev Pharma Pvt. Ltd. (IN) 2024-06-19 EP claimed
CN-118019738-A Small molecule urea derivatives as STING antagonists 库拉德夫制药私人有限公司 2024-05-10 CN claimed
WO-2023017452-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS CURADEV PHARMA PVT. LTD. (IN) 2023-02-16 WO claimed
US-20240360119-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS CURADEV PHARMA PVT. LTD. (IN) 2024-10-31 US disclosed
EP-4384268-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS Curadev Pharma Pvt. Ltd. (IN) 2024-06-19 EP disclosed
CN-118019738-A Small molecule urea derivatives as STING antagonists 库拉德夫制药私人有限公司 2024-05-10 CN disclosed
WO-2023017452-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS CURADEV PHARMA PVT. LTD. (IN) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360119-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS STING1, CGAS, SSB MAPT 2509/4885KDM4E 3534/4885ALDH1A1 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.